Daily Cosmetic Research Analysis
Three studies stand out today: a flexible, surface-lighting microLED skin patch demonstrated clinical benefits for pore tightening and skin rejuvenation; alcohol-based 2% chlorhexidine reduced catheter-related bloodstream infections in neonates without increasing skin injury; and perioperative interstitial brachytherapy achieved comparable local control with superior objective cosmesis versus whole-breast irradiation after breast-conserving surgery.
Summary
Three studies stand out today: a flexible, surface-lighting microLED skin patch demonstrated clinical benefits for pore tightening and skin rejuvenation; alcohol-based 2% chlorhexidine reduced catheter-related bloodstream infections in neonates without increasing skin injury; and perioperative interstitial brachytherapy achieved comparable local control with superior objective cosmesis versus whole-breast irradiation after breast-conserving surgery.
Research Themes
- Wearable phototherapy and device-driven cosmetic dermatology
- Neonatal infection prevention and antisepsis strategies
- Breast-conserving radiotherapy optimization with cosmetic outcomes
Selected Articles
1. Flexible, surface-lighting MicroLED skin patch for multiple human skincare.
This engineering–clinical study introduces a flexible surface-lighting microLED patch that delivers uniform, high-density irradiation while conforming to skin. Early clinical testing demonstrated pore tightening and skin rejuvenation, suggesting a non-invasive, home-use phototherapy platform with improved light delivery versus conventional LEDs.
Impact: Offers a novel wearable phototherapy platform with clinical evidence of cosmetic benefit, addressing longstanding limitations of flexibility and uniformity in LED-based skin treatment.
Clinical Implications: May enable more effective, comfortable, and adherent at-home phototherapy for pore and rejuvenation indications, potentially reducing clinic visits and improving outcomes.
Key Findings
- Developed a flexible, surface-lighting microLED (FSLED) patch with uniform emission and high mechanical flexibility via pick-and-place transfer.
- Designed for efficient, even light delivery by conformal contact with skin, enabling high-density irradiation over large areas.
- Clinical trials demonstrated improvements in pore tightening and skin rejuvenation.
Methodological Strengths
- Integration of materials engineering with clinical testing to demonstrate translational relevance
- Device architecture enabling uniform irradiation and skin conformity
Limitations
- Sample size and trial design details (randomization, controls, duration) are not specified in the abstract
- Long-term safety, durability, and head-to-head comparisons with standard phototherapy devices are not reported
Future Directions: Conduct randomized controlled trials with standardized endpoints, dose–response optimization, and long-term safety monitoring; evaluate indications beyond rejuvenation (acne, dyschromia, wound healing).
As the global population ages, concerns regarding aesthetic appearance have increased. Wearable light-emitting diode (LED) devices have received significant attention in the cosmetic fields due to their non-invasive, non-thermal, home-use characteristics. However, conventional bulk LED chips have limitations in flexibility and uniform irradiation, hindering efficient light penetration into the skin. Here, we introduce a flexible, surface-lighting microLED (FSLED) patch with uniform light-emission for various skincare applications. The FSLED was fabricated using a pick-and-place transfer technique, which allows for high-density irradiation over the large area, while maintaining outstanding mechanical flexibility. In addition, the FSLED was designed to deliver light efficiently and emit light evenly by conforming to the skin. Finally, we prove the effect of the FSLED for pore tightening and skin rejuvenation through clinical trials.
2. Neonatal skin antisepsis with alcohol-based compared to aqueous 2% chlorhexidine, used in moderate preterm infants or extremely preterm infants after the first week of life, is safe and may be associated with a reduced incidence of catheter-related bloodstream infections.
In a double-cohort comparison across two 3-year periods with a 1-year washout, alcohol-based 2% chlorhexidine for neonatal skin antisepsis reduced CRBSI incidence density by about half (OR 0.45) versus aqueous 2% chlorhexidine, without increasing skin lesions. Absolute risk reduction was 3.9% (NNT 25).
Impact: Large, pragmatic evaluation suggests a safer, more effective antisepsis regimen for neonates that could change infection-prevention protocols.
Clinical Implications: Consider adopting alcohol-based 2% chlorhexidine for neonatal line antisepsis beyond the first week of life, with ongoing skin monitoring, to reduce CRBSI.
Key Findings
- Alcohol-based 2% chlorhexidine reduced CRBSI incidence density versus aqueous 2% (4.03 vs 9.05 per 1000 line-days; OR 0.45, 95% CI 0.29–0.68).
- Absolute risk reduction was 3.9% with a number needed to treat of 25.
- Skin lesion rates were similar between periods; erythema was most common (5.1% vs 4.2%).
- In extremely preterm infants within the first week, the reduction was similar in magnitude but not statistically significant.
Methodological Strengths
- Large sample size across two multi-year periods with a defined washout interval
- Clinically meaningful outcomes (CRBSI) with effect estimates (OR, ARR, NNT)
Limitations
- Nonrandomized before–after design susceptible to temporal and practice changes
- Extremely preterm infants in first week continued aqueous chlorhexidine, limiting generalizability for this subgroup
Future Directions: Prospective randomized trials or interrupted time series with adjustment for secular trends; evaluate optimal timing in extremely preterm infants and skin safety profiling.
BACKGROUND: Skin antisepsis is one of the most important bundle measures to decrease central line-related bloodstream infections (CRBSIs). However, in the neonatal population, the use of alcoholic chlorhexidine is limited by the risk of skin lesions. OBJECTIVE: We hypothesised that skin antisepsis with alcohol-based 2% chlorhexidine instead of aqueous 2% chlorhexidine could reduce the incidence of CRBSI without increasing skin complications. DESIGN: We conducted a double cohort study comparing two periods of 3 years, first using aqueous and second using alcohol-based chlorhexidine, leaving a 1-year washout interval between them. In extremely preterm infants, aqueous chlorhexidine was used during the first week of life in both periods. RESULTS: A total of 1783 patients and 2493 episodes of central line catheter were analysed. There were no statistically significant differences in clinical and demographic data from infants in both periods. There was a significant reduction in the pooled incidence density of CRBSI in the second compared with the first period (4.03 vs 9.05 episodes/1000 central line days, OR 0.45 (95% CI 0.29 to 0.68)). The overall absolute risk reduction was 0.039 (95% CI 0.023 to 0.056) and the number needed to treat was 25. A similar but not significant reduction of the small number of CRBSI was observed in extremely preterm infants within the first week of life OR 0.43 (95% CI 0.134 to 1.379). No statistically significant differences in skin lesions were observed between periods, making erythema the most common injury(5.1% vs 4.2%). RELEVANCE: Alcohol-based 2% chlorhexidine as a skin antiseptic could reduce the incidence of CRBSI in neonates without producing an increase in skin lesions.
3. Long-term local control and cosmesis of perioperative interstitial brachytherapy for partial breast irradiation following breast-conserving surgery.
In this single-institution retrospective comparison (PIB n=577; WBI n=241) with 10-year follow-up, perioperative interstitial brachytherapy achieved local control comparable to whole-breast irradiation after breast-conserving surgery, while objective cosmesis was significantly better (83.7% vs 68.1% excellent/good). Age <50 years independently predicted local recurrence.
Impact: Provides the largest long-term dataset suggesting PIB can maintain oncologic control while improving objective cosmesis versus WBI, informing patient-centered radiotherapy selection.
Clinical Implications: For appropriately selected BCS patients (e.g., age ≥40, ≤3 cm, node-negative/micrometastasis), perioperative interstitial brachytherapy may be considered to optimize cosmesis without compromising local control.
Key Findings
- Local recurrence rates were similar between PIB and WBI (3.8% vs 3.3%; P=0.73) over 10 years.
- Objective cosmesis favored PIB (83.7% excellent/good) over WBI (68.1%; P<0.005); subjective assessments were numerically higher with PIB (89.5% vs 84.5%; P=0.26).
- Age <50 years was an independent risk factor for local recurrence on multivariate analysis.
- PIB delivered 32 Gy in 8 fractions immediately after BCS; WBI delivered 50 Gy in 25 fractions.
Methodological Strengths
- Large single-institution cohort with 10-year follow-up
- Both subjective and objective cosmetic endpoints plus multivariate analysis
Limitations
- Retrospective, nonrandomized design with potential selection bias
- Single-center study; generalizability may be limited
Future Directions: Prospective comparative trials of perioperative interstitial brachytherapy versus other partial-breast techniques with standardized cosmesis and QoL metrics; subgroup analyses (e.g., younger patients).
PURPOSE: Multicatheter interstitial brachytherapy (MIB) is an established technique of partial breast irradiation (PBI). However, postoperative catheter implant is an invasive, inconvenient, and skillful procedure. In this study, local control and cosmesis of perioperative interstitial brachytherapy (PIB) by intraoperative catheter implant were evaluated by comparing with those of whole breast irradiation (WBI) following breast-conserving surgery (BCS). METHODS: Between October 2007 and August 2019, consequent patients who underwent either PIB or WBI following BCS were included. In general, additional indications for PIB to WBI included age ≥ 40 years, tumor ≤ 3 cm, and pN0 or pNmi. WBI was initiated with a total dose of 50 Gy in 25 fractions, whereas PBI was delivered immediately following BCS at 32 Gy in eight fractions. Local recurrence (LR) was the primary endpoint, and subjective and objective cosmetic outcomes at 5 years using the Harvard Cosmesis Scale and BCCT.core software, respectively, were the secondary endpoints. RESULTS: During the 10-year follow-up, the crude rate of LR was 3.8% (95% confidence interval [CI] 2.3-5.4) in 577 patients receiving PIB and 3.3% (95% CI 1.1-5.6) in 241 patients receiving WBI (P = 0.73). The 5- and 10-year LR-free survival rates in the PBI and WBI cohorts were 97.9% versus 97.9% and 95.4% versus 96.8%, respectively (P = 0.64). Multivariate analysis selected age < 50 years as an independent risk factor for LR. Excellent or good cosmesis in the PBI and WBI cohorts assessed by subjective and objective measures was 89.5% versus 84.5% (P = 0.26) and 83.7% versus 68.1% (P < 0.005), respectively. CONCLUSIONS: Although this study was based on a retrospective chart review in a single institution, the largest series of data with a long follow-up suggested that acceptable local tumor control and cosmesis were achieved following PIB compared with WBI.